Email Updates

Search form

You are here

18 OCTOBER 2019 VOLUME 20 ISSUE 40

Media Coverage

  • Switching from the older version of tenofovir, tenofovir disoproxil fumarate (TDF), to the new one, tenofovir alafenamide (TAF), is associated with an increase in body mass index (BMI) and atherosclerotic cardiovascular disease risk, the National AIDS Treatment Advocacy Project (NATAP) reports. These findings from a study of people on antiretroviral (ARV) treatment may apply not just to people living with HIV but also to HIV-negative individuals on pre-exposure prophylaxis (PrEP).

    October 18, 2019
    POZ
  • Given a choice between free online self-testing and online self-sampling for HIV, the majority of people chose self-testing. But self-sampling was chosen by a substantial minority, according to a UK pilot study recently published in the International Journal of STD & AIDS.

    October 17, 2019
    General
    aidsmap
  • Five months ago, Gilead announced it would donate 2.4 million bottles of emtricitabine/tenofovir disoproxil fumarate (Truvada) as pre-exposure prophylaxis (PrEP) to the federal government to use as part of its Ending the HIV Epidemic by 2030 initiative.

    October 16, 2019
    The BodyPro
  • It’s been five years since the Fast-Track Cities initiative was launched in Paris on World AIDS Day 2014, when 26 mayors from cities around the world signed a bold declaration to address the HIV epidemic.

    October 16, 2019
    General
    HIV Plus Mag
  • Half of those attending HIV clinics in South Africa and Kenya were eligible to start HIV treatment after simple checks that could be performed by any healthcare worker, and same-day treatment initiation modestly improved the uptake of antiretroviral therapy (ART), results of a randomised trial published in the journal PLOS Medicine show.

    October 16, 2019
    aidsmap
  • “You better get your things in order, you probably have about six months to live,” the nurse told Loreen Willenberg upon returning test results that showed she was HIV-positive in July 1992.

    October 16, 2019
    General
    Leapsmag
  • A medical landmark that might call for fanfare -- a second drug to prevent HIV infection -- is receiving boos from HIV/AIDS advocates who say its rollout could be a step backward, not forward, in access to HIV prevention. In early October, the US Food and Drug Administration (FDA) approved Descovy (emtricitabine/tenofovir alafenamide), manufactured by Gilead Sciences, for men who have sex with men and transgender women as a daily pill for pre-exposure prophylaxis, or PrEP.

    October 15, 2019
    The Body
  • Shoved, cursed and ridiculed, Nisha’s hospital visits were always stressful as a transgender woman and got worse after she was diagnosed as HIV-positive. But a new app introduced as part of a drive to end an HIV epidemic in India by 2030 is providing her and the transgender community better access to doctors, lifesaving drugs - and hope - although it has raised concerns about digital privacy.

    October 15, 2019
    General, Treatment
    Reuters
  • Switching from an antiretroviral treatment (ART) regimen containing tenofovir disoproxil fumarate (TDF) to a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (ECETA) can improve bone density and kidney safety in those aged 60 and above, a new study finds.

    October 15, 2019
    Avert
  • The University of North Carolina (UNC) Project says it has completed studies on vaginal ring and is awaiting approval from regulators. The ring will be used by women as a method of preventing HIV as it offers 73 percent protection.

    October 15, 2019
    Malawi24
  • Heroin is the main drug taken by injection in Kenya. Mostly found and used in Kenya’s big cities – Mombasa and Nairobi – it’s hard to know just how widespread heroin use is. But estimates range between 18,000 and 33,000 people. There are concerns that heroin use is growing but also concern over the high HIV infection rates of users, particularly among women. Injection drug behaviours are recognised as key facilitators of HIV transmission.

    October 14, 2019
    General
    The Conversation
  • Around half a million gay men across Europe are missing out on a treatment that is proven to stop transmission of HIV and is a cornerstone of global prevention efforts.

    October 14, 2019
    Telegraph
  • The Children’s Investment Fund Foundation (CIFF) has financed the Global Fund to Fight AIDS with $25 million (about sh93b) dedicated to scaling HIV self-testing in sub-Saharan Africa.

    October 14, 2019
    General
    New Vision

Published Research

Announcements